Physician profile
David Esparaz
NPI 1891140174
$8,302.52
in general payments reported to CMS, 2019-2025
24 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $5,000 · 2021: $371 · 2022: $458 · 2023: $321 · 2024: $1,479 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,473.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $5,000.00 | 2020 | |
| Abbvie INC. | $713.65 | 2021-2025 | |
| Nevro Corp. | $461.11 | 2023-2024 | Senza |
| Si-Bone, INC. | $356.29 | 2021-2022 | |
| Abbott Laboratories | $306.10 | 2022-2025 | Eterna, Proclaim |
| Collegium Pharmaceutical, INC. | $252.95 | 2024-2025 | Belbuca, Xtampza, Nucynta |
| Boston Scientific Corporation | $190.76 | 2024 | |
| Nalu Medical, INC. | $173.04 | 2023 | Nalu Neurostimulation System |
| Globus Medical, INC. | $149.85 | 2025 | Senza |
| Medtronic, INC. | $136.12 | 2021-2025 | Intellis Adaptivestim |
| Spinefrontier, INC. | $105.42 | 2024 | Inspan, Sijfuse |
| Scilex Pharmaceuticals INC. | $76.89 | 2024-2025 | |
| Saluda Medical Americas, INC. | $72.05 | 2024-2025 | Evoke |
| Biohaven Pharmaceutical Holding Company LTD. | $57.61 | 2022 | |
| Spinal Simplicity, LLC | $50.47 | 2024 | Ha Minuteman G3-R |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36.37 | 2023 | |
| Merz Pharmaceuticals, LLC | $25.00 | 2025 | Xeomin |
| Vertex Pharmaceuticals Incorporated | $24.71 | 2025 | |
| Avanos Medical | $22.98 | 2021 | |
| Kite Pharma, INC. | $22.75 | 2024 | Yescarta |
| Biohaven Pharmaceuticals, INC. | $21.66 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.33 | 2024 | Horizant |
| Ibsa Pharma INC. | $14.26 | 2024 | Tirosint, Licart |
| Bioventus LLC | $14.15 | 2025 | Xcell |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Esparaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.